New Stock Message | Anchormore Biotech Files to List on Hong Kong Stock Exchange, Specializing in Developing T-Cell Engagers for Treating Various Cancers and Autoimmune Diseases

According to the China Fortune Financial APP, as disclosed by the Hong Kong Stock Exchange on June 17th, Anmai Biotechnology Co., Ltd. has submitted an application for listing on the main board of the Hong Kong Stock Exchange, with Citic Securities and CMB International as joint sponsors.